GlobeNewswire: Revance Therapeutics, Inc Contains the last 10 of 65 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T06:39:53ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2016/06/13/848193/0/en/Revance-Reports-Results-for-RT001-Topical-Phase-3-Trial-for-Lateral-Canthal-Lines.html?f=22&fvtc=4&fvtv=20951Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines2016-06-13T20:01:00Z<![CDATA[Revance to host conference call at 1:30 pm PDT (4:30 pm EDT) today Revance to host conference call at 1:30 pm PDT (4:30 pm EDT) today]]>https://www.globenewswire.com/news-release/2016/06/02/845833/0/en/Revance-Expands-Botulinum-Toxin-Assets-by-Acquiring-Intellectual-Property-IP-Portfolio.html?f=22&fvtc=4&fvtv=20951Revance Expands Botulinum Toxin Assets by Acquiring Intellectual Property (IP) Portfolio2016-06-02T22:12:36Z<![CDATA[- Portfolio covers diverse and novel indications, compositions and formulations -]]>https://www.globenewswire.com/news-release/2016/05/31/844934/0/en/Revance-to-Participate-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=20951Revance to Participate in Upcoming Investor Conferences 2016-05-31T20:05:00Z<![CDATA[NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming investor conferences.]]>https://www.globenewswire.com/news-release/2016/05/09/837903/0/en/Revance-Releases-First-Quarter-2016-Results.html?f=22&fvtc=4&fvtv=20951Revance Releases First Quarter 2016 Results2016-05-09T20:05:00Z<![CDATA[- Completes Enrollment in REALISE 1 Phase 3 Trial for RT001 Topical for Crow’s Feet Lines –- Moves Phase 2 Dose-Escalating Trial for RT002 Injectable for Cervical Dystonia into Second Cohort -]]>https://www.globenewswire.com/news-release/2016/04/25/832425/0/en/Revance-Therapeutics-to-Release-First-Quarter-2016-Financial-Results-Monday-May-9-2016.html?f=22&fvtc=4&fvtv=20951Revance Therapeutics to Release First Quarter 2016 Financial Results Monday, May 9, 20162016-04-25T20:01:00Z<![CDATA[Conference Call Scheduled for Monday, May 9, 2016 at 4:30pm ET Conference Call Scheduled for Monday, May 9, 2016 at 4:30pm ET]]>https://www.globenewswire.com/news-release/2016/03/14/819622/0/en/Revance-Therapeutics-Expands-Leadership-Team-Appoints-Roman-G-Rubio-MD-MBA-as-Senior-Vice-President-of-Clinical-Development.html?f=22&fvtc=4&fvtv=20951Revance Therapeutics Expands Leadership Team, Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development2016-03-14T20:05:00Z<![CDATA[NEWARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced a key addition to its leadership team with the appointment of Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development, effective immediately. Dr. Rubio will report to Chief Operating Officer Abhay Joshi, and will lead the company’s clinical development team, focusing on further accelerating the advancement of Revance’s neurotoxin development programs.]]>https://www.globenewswire.com/news-release/2016/03/05/817159/0/en/Revance-Announces-Late-Breaking-Podium-Presentation-of-Positive-6-Month-Duration-Results-for-BELMONT-Phase-2-Active-Comparator-Study-of-Injectable-RT002-at-the-74th-Annual-Meeting-.html?f=22&fvtc=4&fvtv=20951Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology2016-03-05T18:45:00Z<![CDATA[- Findings confirm statistically significantly greater duration of effect for RT002 compared to BOTOX® Cosmetic - - 40U dose of RT002 planned to enter pivotal Phase 3 study in the second half of 2016 -]]>https://www.globenewswire.com/news-release/2016/03/02/816358/0/en/Revance-Releases-Fourth-Quarter-and-Full-Year-2015-Results.html?f=22&fvtc=4&fvtv=20951Revance Releases Fourth Quarter and Full Year 2015 Results2016-03-02T21:05:00Z<![CDATA[- Announces 2016 Outlook -- On Track to Achieve Multiple Clinical Development Milestones in 2016 -]]>https://www.globenewswire.com/news-release/2016/02/23/813373/0/en/Revance-to-Participate-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=20951Revance to Participate in Upcoming Investor Conferences2016-02-23T21:05:00Z<![CDATA[NEWARK, Calif., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today that the Company will be participating in two upcoming investor conferences.]]>https://www.globenewswire.com/news-release/2016/02/17/811608/0/en/Revance-Therapeutics-to-Release-Fourth-Quarter-and-Full-Year-2015-Financial-Results-Wednesday-March-2-2016.html?f=22&fvtc=4&fvtv=20951Revance Therapeutics to Release Fourth Quarter and Full Year 2015 Financial Results Wednesday, March 2, 20162016-02-17T21:05:00Z<![CDATA[Conference Call Scheduled for Wednesday, March 2, 2016 at 4:30pm ET Conference Call Scheduled for Wednesday, March 2, 2016 at 4:30pm ET]]>